Breast Cancer

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

Shared insight on key driver mutations and corresponding precision medicine in the setting of breast cancer management.

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

The World Health Organization has released new framework guidelines with the goal of saving 2.5 million lives from breast cancer by 2040 through a combination of early detection, timely diagnosis, and comprehensive management.

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer. 

The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

In recommendations released January 27, 2023, the National Comprehensive Cancer Network now advises physicians to consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of estrogen receptor status, with activating mutations in the HER2 gene as detected by next-generation sequencing of tumor tissue or circulating tumor DNA.

Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.